patient_id stringlengths 12 12 | record_id stringlengths 11 11 | cancer_type stringclasses 1
value | histology stringclasses 3
values | stage_at_diagnosis stringclasses 3
values | driver_mutation stringclasses 7
values | pd_l1_tps_percent int64 5 41 | tmb_mutations_per_mb float64 1.5 25 | age_at_diagnosis int64 38 90 | sex stringclasses 2
values | ecog_performance_status int64 0 4 | smoking_pack_years int64 0 111 | primary_tumor_size_cm float64 2 10 | metastatic_sites_count int64 0 11 | first_line_regimen stringclasses 6
values | overall_survival_months float64 4 83 | censored bool 2
classes | msi_status stringclasses 2
values | record_generation_timestamp stringdate 2026-03-15 05:35:56 2026-03-15 05:36:02 | synthetic_source stringclasses 1
value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ANODE_309204 | REC_0006001 | Non-small cell lung cancer | Adenocarcinoma | III | ROS1 fusion | 29 | 17.3 | 68 | male | 0 | 19 | 8.2 | 0 | entrectinib 600 mg daily | 27.6 | false | MSS | 2026-03-15T05:35:58.329060+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_585256 | REC_0006002 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 31 | 7.8 | 75 | male | 2 | 23 | 3.9 | 4 | sotorasib 960 mg daily | 16.1 | false | MSS | 2026-03-15T05:35:58.329294+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_135323 | REC_0006003 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 26 | 11.7 | 52 | female | 0 | 19 | 5.5 | 2 | sotorasib 960 mg daily | 26.9 | false | MSS | 2026-03-15T05:35:58.329528+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_566367 | REC_0006004 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 23 | 10.8 | 67 | female | 0 | 13 | 4.6 | 6 | osimertinib 80 mg daily | 5 | false | MSS | 2026-03-15T05:35:58.329760+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_932825 | REC_0006005 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 21 | 11.9 | 62 | female | 0 | 15 | 6.8 | 5 | entrectinib 600 mg daily | 9.9 | false | MSI-H | 2026-03-15T05:35:58.329994+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_253121 | REC_0006006 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 17 | 14.2 | 77 | female | 2 | 6 | 6.3 | 6 | entrectinib 600 mg daily | 10.7 | false | MSS | 2026-03-15T05:35:58.330225+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_302168 | REC_0006007 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 28 | 8.9 | 69 | female | 1 | 48 | 3.7 | 2 | carboplatin + paclitaxel + pembrolizumab | 14 | false | MSS | 2026-03-15T05:35:58.330507+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_407256 | REC_0006008 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 23 | 17 | 65 | male | 1 | 11 | 4 | 1 | alectinib 600 mg BID | 18.7 | true | MSS | 2026-03-15T05:35:58.330747+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_282327 | REC_0006009 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 22 | 6 | 70 | female | 4 | 20 | 5.7 | 4 | pembrolizumab 200 mg q3w | 7.1 | true | MSS | 2026-03-15T05:35:58.330973+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_412760 | REC_0006010 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 25 | 13.8 | 63 | female | 0 | 11 | 4.9 | 3 | osimertinib 80 mg daily | 5.9 | true | MSS | 2026-03-15T05:35:58.331209+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_829009 | REC_0006011 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 22 | 11.1 | 75 | female | 2 | 15 | 7.7 | 7 | alectinib 600 mg BID | 8.1 | false | MSS | 2026-03-15T05:35:58.331441+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_613484 | REC_0006012 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 28 | 16.9 | 65 | female | 0 | 11 | 6.3 | 2 | pembrolizumab 200 mg q3w | 23.3 | true | MSI-H | 2026-03-15T05:35:58.331676+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_239233 | REC_0006013 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 22 | 6.5 | 68 | male | 1 | 9 | 5.8 | 5 | alectinib 600 mg BID | 8.3 | true | MSS | 2026-03-15T05:35:58.331910+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_333233 | REC_0006014 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 26 | 7.7 | 71 | female | 1 | 23 | 4.4 | 9 | entrectinib 600 mg daily | 8.4 | true | MSS | 2026-03-15T05:35:58.332194+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_469782 | REC_0006015 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 18 | 10.4 | 74 | female | 0 | 6 | 4.8 | 5 | osimertinib 80 mg daily | 6.9 | false | MSS | 2026-03-15T05:35:58.332436+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_570876 | REC_0006016 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 27 | 15 | 57 | male | 0 | 7 | 3.7 | 2 | alectinib 600 mg BID | 17.4 | true | MSS | 2026-03-15T05:35:58.332672+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_899940 | REC_0006017 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 14 | 13 | 58 | male | 0 | 7 | 4.3 | 5 | entrectinib 600 mg daily | 18.5 | false | MSS | 2026-03-15T05:35:58.332906+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_862384 | REC_0006018 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 21 | 9.8 | 72 | female | 2 | 17 | 4.6 | 1 | alectinib 600 mg BID | 20.9 | true | MSS | 2026-03-15T05:35:58.333132+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_439346 | REC_0006019 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 31 | 17.4 | 62 | female | 1 | 4 | 7.8 | 1 | osimertinib 80 mg daily | 8.7 | false | MSI-H | 2026-03-15T05:35:58.333366+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_726908 | REC_0006020 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 24 | 11.6 | 68 | male | 0 | 23 | 5.1 | 5 | alectinib 600 mg BID | 10.3 | false | MSI-H | 2026-03-15T05:35:58.333647+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_532618 | REC_0006021 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 26 | 4.8 | 65 | male | 1 | 66 | 5.2 | 9 | carboplatin + paclitaxel + pembrolizumab | 22.1 | false | MSS | 2026-03-15T05:35:58.333883+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_648378 | REC_0006022 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 24 | 9.1 | 63 | female | 0 | 17 | 6.9 | 2 | alectinib 600 mg BID | 14 | true | MSS | 2026-03-15T05:35:58.334121+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_305313 | REC_0006023 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 26 | 7 | 58 | male | 0 | 5 | 3.5 | 1 | pembrolizumab 200 mg q3w | 17.2 | true | MSS | 2026-03-15T05:35:58.334360+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_635022 | REC_0006024 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 24 | 14.1 | 78 | female | 2 | 18 | 4.6 | 4 | osimertinib 80 mg daily | 13 | true | MSS | 2026-03-15T05:35:58.334600+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_160055 | REC_0006025 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 27 | 7 | 77 | female | 2 | 15 | 7.4 | 5 | entrectinib 600 mg daily | 12.6 | false | MSS | 2026-03-15T05:35:58.334832+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_768448 | REC_0006026 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 23 | 5 | 77 | female | 2 | 8 | 5.7 | 4 | carboplatin + paclitaxel + pembrolizumab | 4.4 | false | MSS | 2026-03-15T05:35:58.335062+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_874924 | REC_0006027 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 29 | 10.9 | 64 | female | 1 | 0 | 4.9 | 1 | osimertinib 80 mg daily | 18.9 | false | MSS | 2026-03-15T05:35:58.335300+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_207944 | REC_0006028 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 21 | 18.4 | 78 | female | 1 | 13 | 4.8 | 6 | sotorasib 960 mg daily | 13 | true | MSS | 2026-03-15T05:35:58.335536+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_672296 | REC_0006029 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 25 | 12.5 | 80 | female | 1 | 18 | 6.7 | 6 | entrectinib 600 mg daily | 5.3 | false | MSI-H | 2026-03-15T05:35:58.335768+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_420340 | REC_0006030 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 26 | 10.6 | 62 | female | 0 | 12 | 6.4 | 5 | entrectinib 600 mg daily | 10.7 | false | MSI-H | 2026-03-15T05:35:58.336003+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_492993 | REC_0006031 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 22 | 10 | 77 | female | 2 | 16 | 7.4 | 7 | osimertinib 80 mg daily | 7.5 | true | MSS | 2026-03-15T05:35:58.336287+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_404054 | REC_0006032 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 22 | 14.5 | 72 | female | 2 | 20 | 7.5 | 8 | sotorasib 960 mg daily | 13.6 | true | MSI-H | 2026-03-15T05:35:58.336524+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_302664 | REC_0006033 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 21 | 13.3 | 79 | female | 2 | 4 | 3.3 | 7 | osimertinib 80 mg daily | 4 | false | MSS | 2026-03-15T05:35:58.336847+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_602824 | REC_0006034 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 22 | 13.4 | 60 | male | 0 | 18 | 4.5 | 6 | alectinib 600 mg BID | 14.2 | true | MSI-H | 2026-03-15T05:35:58.337090+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_363101 | REC_0006035 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 21 | 16.6 | 53 | female | 0 | 9 | 4.4 | 5 | osimertinib 80 mg daily | 8.2 | false | MSI-H | 2026-03-15T05:35:58.337328+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_880035 | REC_0006036 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 27 | 6 | 63 | female | 1 | 22 | 7 | 1 | sotorasib 960 mg daily | 20 | true | MSS | 2026-03-15T05:35:58.337561+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_311467 | REC_0006037 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 22 | 10.2 | 77 | female | 3 | 2 | 3.6 | 5 | alectinib 600 mg BID | 8.2 | false | MSS | 2026-03-15T05:35:58.337790+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_197936 | REC_0006038 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 25 | 11.1 | 72 | female | 1 | 12 | 3.6 | 7 | sotorasib 960 mg daily | 10.5 | true | MSS | 2026-03-15T05:35:58.338026+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_116825 | REC_0006039 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 23 | 11.9 | 78 | female | 0 | 21 | 4.5 | 4 | osimertinib 80 mg daily | 7.1 | false | MSS | 2026-03-15T05:35:58.338261+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_989479 | REC_0006040 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 33 | 11.1 | 73 | female | 1 | 17 | 5.6 | 4 | pembrolizumab 200 mg q3w | 16.6 | false | MSI-H | 2026-03-15T05:35:58.338495+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_938419 | REC_0006041 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 28 | 13.5 | 77 | female | 2 | 19 | 6.9 | 3 | sotorasib 960 mg daily | 13.8 | false | MSS | 2026-03-15T05:35:58.338727+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_582260 | REC_0006042 | Non-small cell lung cancer | Adenocarcinoma | III | None (PD-L1 high) | 28 | 11.6 | 73 | male | 1 | 9 | 5.5 | 0 | pembrolizumab 200 mg q3w | 25.5 | true | MSI-H | 2026-03-15T05:35:58.338963+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_611750 | REC_0006043 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 24 | 5.1 | 71 | female | 1 | 37 | 6 | 2 | carboplatin + paclitaxel + pembrolizumab | 17.6 | false | MSS | 2026-03-15T05:35:58.339191+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_687689 | REC_0006044 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 28 | 3.5 | 82 | male | 1 | 1 | 5.4 | 6 | carboplatin + paclitaxel + pembrolizumab | 11.9 | false | MSS | 2026-03-15T05:35:58.339424+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_413505 | REC_0006045 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 23 | 8.3 | 68 | female | 1 | 9 | 4.4 | 9 | pembrolizumab 200 mg q3w | 12.4 | true | MSS | 2026-03-15T05:35:58.339652+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_806109 | REC_0006046 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 22 | 5.6 | 72 | male | 2 | 43 | 5.5 | 9 | carboplatin + paclitaxel + pembrolizumab | 11.2 | false | MSS | 2026-03-15T05:35:58.339949+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_606632 | REC_0006047 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 23 | 12.1 | 56 | female | 1 | 23 | 7.7 | 5 | osimertinib 80 mg daily | 12.3 | true | MSS | 2026-03-15T05:35:58.340262+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_703892 | REC_0006048 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 29 | 8.3 | 66 | female | 0 | 8 | 3.9 | 2 | pembrolizumab 200 mg q3w | 23.8 | true | MSS | 2026-03-15T05:35:58.340496+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_220811 | REC_0006049 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 22 | 10.2 | 61 | male | 0 | 8 | 5.2 | 5 | entrectinib 600 mg daily | 14.9 | false | MSI-H | 2026-03-15T05:35:58.340746+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_696900 | REC_0006050 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 18 | 14.3 | 57 | female | 1 | 13 | 6.1 | 6 | osimertinib 80 mg daily | 16.8 | false | MSI-H | 2026-03-15T05:35:58.340982+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_929057 | REC_0006051 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 22 | 8.7 | 61 | female | 0 | 15 | 4.8 | 6 | entrectinib 600 mg daily | 14.6 | true | MSS | 2026-03-15T05:35:58.341215+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_215753 | REC_0006052 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 23 | 10.6 | 70 | female | 1 | 14 | 5.2 | 1 | osimertinib 80 mg daily | 18.4 | false | MSI-H | 2026-03-15T05:35:58.341445+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_752512 | REC_0006053 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 21 | 11.8 | 69 | male | 1 | 7 | 4.5 | 6 | alectinib 600 mg BID | 11.9 | false | MSI-H | 2026-03-15T05:35:58.341681+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_705338 | REC_0006054 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 18 | 13.8 | 69 | female | 0 | 2 | 5.6 | 5 | osimertinib 80 mg daily | 13.1 | true | MSS | 2026-03-15T05:35:58.341915+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_613715 | REC_0006055 | Non-small cell lung cancer | Adenocarcinoma | III | ROS1 fusion | 14 | 11.3 | 59 | female | 1 | 5 | 5.7 | 0 | entrectinib 600 mg daily | 31.9 | false | MSS | 2026-03-15T05:35:58.342151+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_238137 | REC_0006056 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 27 | 15.5 | 70 | female | 0 | 21 | 7.1 | 5 | pembrolizumab 200 mg q3w | 11.4 | true | MSS | 2026-03-15T05:35:58.342381+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_583182 | REC_0006057 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 33 | 10 | 71 | female | 1 | 12 | 4.6 | 4 | entrectinib 600 mg daily | 16.1 | false | MSI-H | 2026-03-15T05:35:58.342612+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_822649 | REC_0006058 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 24 | 11.5 | 65 | male | 1 | 2 | 3.7 | 7 | entrectinib 600 mg daily | 11 | false | MSI-H | 2026-03-15T05:35:58.342845+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_577744 | REC_0006059 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 24 | 9 | 60 | male | 0 | 16 | 5.6 | 8 | osimertinib 80 mg daily | 11.7 | false | MSS | 2026-03-15T05:35:58.343134+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_401295 | REC_0006060 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 22 | 5.5 | 75 | male | 1 | 86 | 2.9 | 1 | carboplatin + paclitaxel + pembrolizumab | 21 | false | MSS | 2026-03-15T05:35:58.343369+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_103657 | REC_0006061 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 24 | 12.4 | 76 | female | 2 | 0 | 5.8 | 6 | osimertinib 80 mg daily | 4 | true | MSI-H | 2026-03-15T05:35:58.343600+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_602372 | REC_0006062 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 25 | 12 | 81 | female | 1 | 14 | 5.4 | 7 | pembrolizumab 200 mg q3w | 14.2 | true | MSI-H | 2026-03-15T05:35:58.343832+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_716070 | REC_0006063 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 20 | 13.2 | 73 | female | 2 | 19 | 7.6 | 6 | entrectinib 600 mg daily | 13.2 | false | MSI-H | 2026-03-15T05:35:58.344065+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_691129 | REC_0006064 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 17 | 14.4 | 66 | female | 1 | 11 | 4.8 | 4 | entrectinib 600 mg daily | 12.4 | false | MSS | 2026-03-15T05:35:58.344335+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_803650 | REC_0006065 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 28 | 1.5 | 84 | female | 1 | 13 | 5.2 | 1 | osimertinib 80 mg daily | 13.4 | false | MSS | 2026-03-15T05:35:58.344566+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_815073 | REC_0006066 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 29 | 16.7 | 60 | female | 0 | 10 | 6.1 | 2 | entrectinib 600 mg daily | 17.6 | true | MSI-H | 2026-03-15T05:35:58.344803+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_684105 | REC_0006067 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 18 | 10.6 | 75 | female | 1 | 18 | 7.3 | 7 | alectinib 600 mg BID | 11.3 | false | MSS | 2026-03-15T05:35:58.345038+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_433776 | REC_0006068 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 22 | 14.9 | 67 | female | 0 | 8 | 4.6 | 4 | osimertinib 80 mg daily | 14.5 | false | MSS | 2026-03-15T05:35:58.345269+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_109576 | REC_0006069 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 20 | 12.8 | 59 | female | 0 | 14 | 6.8 | 4 | entrectinib 600 mg daily | 11.7 | true | MSS | 2026-03-15T05:35:58.345506+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_726528 | REC_0006070 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 24 | 6.8 | 64 | male | 1 | 56 | 7.7 | 5 | carboplatin + paclitaxel + pembrolizumab | 8.8 | false | MSS | 2026-03-15T05:35:58.345740+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_606854 | REC_0006071 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 27 | 4.7 | 70 | female | 1 | 14 | 5.1 | 2 | sotorasib 960 mg daily | 9.8 | true | MSS | 2026-03-15T05:35:58.345968+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_217648 | REC_0006072 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 33 | 21.6 | 70 | female | 1 | 21 | 6.2 | 1 | osimertinib 80 mg daily | 11.1 | false | MSS | 2026-03-15T05:35:58.346247+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_794869 | REC_0006073 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 24 | 16.5 | 74 | female | 3 | 22 | 4 | 4 | osimertinib 80 mg daily | 14.8 | true | MSI-H | 2026-03-15T05:35:58.346485+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_234744 | REC_0006074 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 19 | 10.6 | 57 | male | 0 | 18 | 7.2 | 6 | sotorasib 960 mg daily | 5.3 | true | MSS | 2026-03-15T05:35:58.346719+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_116116 | REC_0006075 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 24 | 4.6 | 67 | male | 1 | 43 | 6.5 | 2 | pembrolizumab 200 mg q3w | 15.9 | false | MSS | 2026-03-15T05:35:58.346950+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_895167 | REC_0006076 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 31 | 14.7 | 60 | female | 1 | 25 | 6.8 | 4 | alectinib 600 mg BID | 5.2 | false | MSS | 2026-03-15T05:35:58.347184+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_398265 | REC_0006077 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 26 | 12.9 | 73 | female | 1 | 24 | 3.9 | 8 | sotorasib 960 mg daily | 8.6 | false | MSS | 2026-03-15T05:35:58.347416+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_936858 | REC_0006078 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 29 | 18.7 | 62 | female | 0 | 10 | 3.3 | 6 | alectinib 600 mg BID | 17.5 | false | MSI-H | 2026-03-15T05:35:58.347650+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_287406 | REC_0006079 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 22 | 5.4 | 62 | male | 0 | 14 | 5.4 | 5 | carboplatin + paclitaxel + pembrolizumab | 11.4 | true | MSS | 2026-03-15T05:35:58.347883+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_101584 | REC_0006080 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 25 | 5.9 | 86 | female | 3 | 39 | 4.3 | 2 | carboplatin + paclitaxel + pembrolizumab | 24.2 | true | MSS | 2026-03-15T05:35:58.348140+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_934262 | REC_0006081 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 23 | 18.6 | 80 | male | 3 | 11 | 3.7 | 7 | alectinib 600 mg BID | 11.5 | false | MSI-H | 2026-03-15T05:35:58.348383+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_126921 | REC_0006082 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 27 | 14.9 | 80 | male | 2 | 18 | 2.8 | 1 | sotorasib 960 mg daily | 22.6 | false | MSI-H | 2026-03-15T05:35:58.348620+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_786531 | REC_0006083 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 20 | 11.6 | 61 | female | 0 | 9 | 6.4 | 5 | osimertinib 80 mg daily | 9.4 | false | MSI-H | 2026-03-15T05:35:58.348857+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_480499 | REC_0006084 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 22 | 6.3 | 68 | female | 1 | 19 | 5.8 | 2 | pembrolizumab 200 mg q3w | 14.2 | false | MSS | 2026-03-15T05:35:58.349084+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_399855 | REC_0006085 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 26 | 17.2 | 74 | female | 2 | 9 | 6.6 | 1 | osimertinib 80 mg daily | 6.7 | false | MSS | 2026-03-15T05:35:58.349364+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_964333 | REC_0006086 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 17 | 7.6 | 66 | female | 1 | 73 | 5.2 | 8 | carboplatin + paclitaxel + pembrolizumab | 9.4 | true | MSS | 2026-03-15T05:35:58.349598+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_200617 | REC_0006087 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 16 | 7.1 | 64 | male | 0 | 41 | 6.5 | 7 | pembrolizumab 200 mg q3w | 17.2 | false | MSS | 2026-03-15T05:35:58.349832+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_380276 | REC_0006088 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 19 | 7.1 | 51 | female | 0 | 16 | 6.8 | 6 | pembrolizumab 200 mg q3w | 12.2 | false | MSS | 2026-03-15T05:35:58.350064+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_399448 | REC_0006089 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 31 | 12 | 71 | male | 3 | 16 | 6 | 0 | entrectinib 600 mg daily | 7.3 | true | MSS | 2026-03-15T05:35:58.350301+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_749640 | REC_0006090 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 11 | 12.6 | 70 | female | 1 | 16 | 3.5 | 7 | sotorasib 960 mg daily | 10.1 | false | MSI-H | 2026-03-15T05:35:58.350530+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_295755 | REC_0006091 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 19 | 3.3 | 71 | female | 2 | 16 | 5.6 | 6 | pembrolizumab 200 mg q3w | 15.4 | true | MSS | 2026-03-15T05:35:58.350758+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_731049 | REC_0006092 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 26 | 17.1 | 58 | male | 1 | 16 | 6.1 | 1 | entrectinib 600 mg daily | 16.6 | true | MSI-H | 2026-03-15T05:35:58.350994+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_512150 | REC_0006093 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 17 | 2.2 | 71 | female | 1 | 38 | 5.7 | 2 | carboplatin + paclitaxel + pembrolizumab | 18.8 | true | MSS | 2026-03-15T05:35:58.351220+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_888322 | REC_0006094 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 28 | 15.2 | 71 | female | 3 | 18 | 5.5 | 2 | pembrolizumab 200 mg q3w | 16.8 | false | MSI-H | 2026-03-15T05:35:58.351456+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_401356 | REC_0006095 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 24 | 6.6 | 71 | female | 1 | 23 | 5.3 | 7 | pembrolizumab 200 mg q3w | 4 | true | MSS | 2026-03-15T05:35:58.351685+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_562247 | REC_0006096 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 11 | 10.6 | 70 | female | 2 | 15 | 8.5 | 6 | osimertinib 80 mg daily | 9.9 | true | MSS | 2026-03-15T05:35:58.351916+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_372088 | REC_0006097 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 24 | 10.9 | 63 | female | 0 | 13 | 3.5 | 1 | entrectinib 600 mg daily | 13.7 | false | MSS | 2026-03-15T05:35:58.352201+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_636448 | REC_0006098 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 23 | 10.9 | 71 | female | 2 | 17 | 8 | 1 | entrectinib 600 mg daily | 20.8 | false | MSI-H | 2026-03-15T05:35:58.352486+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_780438 | REC_0006099 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 26 | 2.5 | 65 | male | 1 | 74 | 5.6 | 2 | carboplatin + paclitaxel + pembrolizumab | 25.6 | false | MSS | 2026-03-15T05:35:58.352735+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_471644 | REC_0006100 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 33 | 7.5 | 69 | female | 0 | 48 | 5.4 | 9 | pembrolizumab 200 mg q3w | 10.5 | false | MSS | 2026-03-15T05:35:58.352964+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.